[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Fatty Acid Oxidation Disorders (FAODs) - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: F6B0852CF078EN
DelveInsight

US$ 3,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Fatty Acid Oxidation Disorders (FAODs) - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Fatty Acid Oxidation Disorders (FAODs) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2019-2032

Fatty Acid Oxidation Disorders (FAODs) Understanding

The DelveInsight Fatty Acid Oxidation Disorders (FAODs) epidemiology report gives a thorough understanding of the Fatty Acid Oxidation Disorders (FAODs) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Fatty Acid Oxidation Disorders (FAODs) in the US, Europe, and Japan. The report covers the detailed information of the Fatty Acid Oxidation Disorders (FAODs) epidemiology scenario in seven major countries (US, EU5, and Japan).

Fatty Acid Oxidation Disorders (FAODs) Epidemiology Perspective by DelveInsight

The Fatty Acid Oxidation Disorders (FAODs) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Fatty Acid Oxidation Disorders (FAODs) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Fatty Acid Oxidation Disorders (FAODs) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Fatty Acid Oxidation Disorders (FAODs) Detailed Epidemiology Segmentation

The Fatty Acid Oxidation Disorders (FAODs) epidemiology covered in the report provides historical as well as forecasted Fatty Acid Oxidation Disorders (FAODs) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Fatty Acid Oxidation Disorders (FAODs) report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report
  • The Fatty Acid Oxidation Disorders (FAODs) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Fatty Acid Oxidation Disorders (FAODs) Epidemiology Report and Model provide an overview of the global trends of Fatty Acid Oxidation Disorders (FAODs) in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Fatty Acid Oxidation Disorders (FAODs) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM for the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Fatty Acid Oxidation Disorders (FAODs)
  • The report provides the segmentation of the Fatty Acid Oxidation Disorders (FAODs) epidemiology
Report Highlights
  • 11-year Forecast of Fatty Acid Oxidation Disorders (FAODs) epidemiology
  • 7MM Coverage
  • Prevalent and Diagnosed Cases of Fatty Acid Oxidation Disorders (FAODs)
  • Cases of Fatty Acid Oxidation Disorders (FAODs) by Mutation Types
  • Fatty Acid Oxidation Disorders (FAODs) Cases associated with Clinical Manifestations
KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Fatty Acid Oxidation Disorders (FAODs)?
  • What are the key findings pertaining to the Fatty Acid Oxidation Disorders (FAODs) epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
  • What would be the total number of patients of Fatty Acid Oxidation Disorders (FAODs) across the 7MM during the forecast period (2019-2032)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
  • What is the disease risk, burden and unmet needs of Fatty Acid Oxidation Disorders (FAODs)?
  • What are the currently available treatments of Fatty Acid Oxidation Disorders (FAODs)?
Reasons to buy

The Fatty Acid Oxidation Disorders (FAODs) Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global Fatty Acid Oxidation Disorders (FAODs) market
  • Quantify patient populations in the global Fatty Acid Oxidation Disorders (FAODs) market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Fatty Acid Oxidation Disorders (FAODs) therapeutics in each of the markets covered
  • Understand the magnitude of Fatty Acid Oxidation Disorders (FAODs) population by its epidemiology
  • The Fatty Acid Oxidation Disorders (FAODs) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF FATTY ACID OXIDATION DISORDERS (FAODS)

3. FATTY ACID OXIDATION DISORDERS (FAODS): DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Fatty Acid Oxidation Disorders (FAODs) Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Fatty Acid Oxidation Disorders (FAODs) Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Fatty Acid Oxidation Disorders (FAODs) Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Fatty Acid Oxidation Disorders (FAODs) Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Fatty Acid Oxidation Disorders (FAODs) Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Fatty Acid Oxidation Disorders (FAODs) Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Fatty Acid Oxidation Disorders (FAODs) Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Fatty Acid Oxidation Disorders (FAODs) Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Fatty Acid Oxidation Disorders (FAODs) Treatment and Management
6.2. Fatty Acid Oxidation Disorders (FAODs) Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report


LIST OF TABLES

List of Table:
Table 1: Fatty Acid Oxidation Disorders (FAODs) Epidemiology in 7MM (2019-2032)
Table 2: Fatty Acid Oxidation Disorders (FAODs) Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Fatty Acid Oxidation Disorders (FAODs) Epidemiology in the United States (2019-2032)
Table 4: Fatty Acid Oxidation Disorders (FAODs) Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Fatty Acid Oxidation Disorders (FAODs) Epidemiology in Germany (2019-2032)
Table 6: Fatty Acid Oxidation Disorders (FAODs) Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Fatty Acid Oxidation Disorders (FAODs) Epidemiology in France (2019-2032)
Table 8: Fatty Acid Oxidation Disorders (FAODs) Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Fatty Acid Oxidation Disorders (FAODs) Epidemiology in Italy (2019-2032)
Table 10: Fatty Acid Oxidation Disorders (FAODs) Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Fatty Acid Oxidation Disorders (FAODs) Epidemiology in Spain (2019-2032)
Table 12: Fatty Acid Oxidation Disorders (FAODs) Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Fatty Acid Oxidation Disorders (FAODs) Epidemiology in the United Kingdom (2019-2032)
Table 14: Fatty Acid Oxidation Disorders (FAODs) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Fatty Acid Oxidation Disorders (FAODs) Epidemiology in Japan (2019-2032)
Table 16: Fatty Acid Oxidation Disorders (FAODs) Diagnosed and Treatable Cases in Japan (2019-2032)


LIST OF FIGURES

List of Figures
Figure 1 Fatty Acid Oxidation Disorders (FAODs) Epidemiology in 7MM (2019-2032)
Figure 2 Fatty Acid Oxidation Disorders (FAODs) Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Fatty Acid Oxidation Disorders (FAODs) Epidemiology in the United States (2019-2032)
Figure 4 Fatty Acid Oxidation Disorders (FAODs) Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Fatty Acid Oxidation Disorders (FAODs) Epidemiology in Germany (2019-2032)
Figure 6 Fatty Acid Oxidation Disorders (FAODs) Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Fatty Acid Oxidation Disorders (FAODs) Epidemiology in France (2019-2032)
Figure 8 Fatty Acid Oxidation Disorders (FAODs) Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Fatty Acid Oxidation Disorders (FAODs) Epidemiology in Italy (2019-2032)
Figure 10 Fatty Acid Oxidation Disorders (FAODs) Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Fatty Acid Oxidation Disorders (FAODs) Epidemiology in Spain (2019-2032)
Figure 12 Fatty Acid Oxidation Disorders (FAODs) Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Fatty Acid Oxidation Disorders (FAODs) Epidemiology in the United Kingdom (2019-2032)
Figure 14 Fatty Acid Oxidation Disorders (FAODs) Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Fatty Acid Oxidation Disorders (FAODs) Epidemiology in Japan (2019-2032)
Figure 16 Fatty Acid Oxidation Disorders (FAODs) Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report


More Publications